ENRUHE
PF-Atlas › Clinical Trials › NCT05684289

A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants and Japanese Participants

BMS-986278 · Phase 1

Registry ID
NCT05684289
Phase
Phase 1
Status
Completed
Drug / intervention
BMS-986278
Sponsor
Bristol-Myers Squibb
Start
2023-01-03

About this trial

BMS-986278 is evaluated in NCT05684289, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Bristol-Myers Squibb. Current status: Completed.

View NCT05684289 on ClinicalTrials.gov →

Explore related

Admilparant / BMS-986278 — Treatment profileAll BMS-986278 trialsAll IPF trials

Related trials

BMS-986278 — NCT05932303BMS-986278 — NCT06003426BMS-986278 — NCT05985590BMS-986278 — NCT06025578BMS-986278 — NCT03981094BMS-986278 — NCT07441408
Medical disclaimer. This page summarizes public trial data for NCT05684289 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.